Published on 16 May 2023 on Simply Wall St. via Yahoo Finance

Revenue Downgrade: Here's What Analysts Forecast For HOOKIPA Pharma Inc. (NASDAQ:HOOK)

Market forces rained on the parade of HOOKIPA Pharma Inc. (NASDAQ:HOOK) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. Investors however, have been notably more optimistic about HOOKIPA Pharma recently, with the stock price up a noteworthy 20% to US$1.86 in the past week. With such a sharp increase, it seems brokers may have seen something that is not yet being priced in by the wider market.

Following the latest downgrade, the six analysts covering HOOKIPA Pharma provided consensus estimates of US$15m revenue in 2023, which would reflect a measurable 3.5% decline on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$18m in 2023. It looks like forecasts have become a fair bit less optimistic on HOOKIPA Pharma, given the measurable cut to revenue estimates.

See our latest analysis for HOOKIPA Pharma